OPCH
NEUTRAL
$28.34
Live
Option Care Health, Inc. · NASDAQ
Target $40.09
(+41.5%)
$24.24
52W Range
$36.8
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$4.45B
P/E
22.32
ROE
15.2%
Profit margin
3.7%
Debt/Equity
0.96
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
OPCH exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency. However, the stock is trading at a significant premium to its Graham Number ($15.54) and Intrinsic Value ($11.37), suggesting a valuation disconnect based on defensive metrics. While analysts maintain a 'strong_buy' rating with a target of $40.09, this optimism is countered by bearish insider selling and a completely bearish technical trend. The outlook is balanced between strong balance sheet health and an overextended valuation relative to current earnings growth.
Key Strengths
Strong Piotroski F-Score (7/9) indicating high financial health
Healthy ROE of 15.20% and ROA of 6.14%
Attractive Price/Sales ratio of 0.79
Strong analyst consensus with a high target price of $40.09
Manageable Debt/Equity ratio (0.96) and stable Current Ratio (1.52)
Key Risks
Significant overvaluation relative to Graham and Intrinsic value models
Bearish insider sentiment with recent selling activity
Negative technical trend (0/100)
Sluggish YoY earnings growth (1.30%) and negative Q/Q earnings growth (-2.70%)
Thin profit margins (3.67%) leaving little room for operational error
AI Fair Value Estimate
Based on comprehensive analysis
$21.45
-24.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
48
Moderate
35
50
70
85
0
AI Verdict
Hold
Key drivers: Strong operational health (Piotroski), Valuation premium over deterministic models, Divergence between analyst targets and insider behavior
Confidence
80%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Sales (0.79)
- Forward P/E (13.33) is lower than current P/E
Watchpoints
- Price ($28.34) is well above Graham Number ($15.54)
- Price is significantly higher than Intrinsic Value ($11.37)
Future
50/100
Ref Growth rates
Positives
- Steady revenue growth (8.80%)
- Strong analyst price targets
Watchpoints
- Stagnant YoY earnings growth (1.30%)
- Recent quarterly earnings misses (1/4 beats)
Past
70/100
Ref Historical trends
Positives
- Long-term history of earnings beats
- Positive 5-year price change (+46.4%)
Watchpoints
- Poor 1-year performance (-12.2%)
Health
85/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 7/9
- Current Ratio of 1.52
Watchpoints
- Altman Z-Score not provided
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$28.34
Analyst Target
$40.09
Upside/Downside
+41.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OPCH and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OPCH
Option Care Health, Inc.
Primary
|
+46.4% | -9.8% | -12.2% | +4.5% | -3.6% | -2.8% |
|
FOLD
Amicus Therapeutics, Inc.
Peer
|
+55.8% | +30.6% | +110.0% | +75.0% | +0.8% | +0.2% |
|
ALKS
Alkermes plc
Peer
|
+40.1% | +3.5% | -17.4% | +2.9% | -20.5% | -3.0% |
|
RDNT
RadNet, Inc.
Peer
|
+171.5% | +117.6% | +21.3% | -21.5% | -2.6% | +8.9% |
|
MMSI
Merit Medical Systems, Inc.
Peer
|
+15.0% | -8.9% | -24.4% | -12.4% | +2.0% | +4.7% |
OPC
Option Care Health, Inc.
Primary
5Y
+46.4%
3Y
-9.8%
1Y
-12.2%
6M
+4.5%
1M
-3.6%
1W
-2.8%
FOL
Amicus Therapeutics, Inc.
Peer
5Y
+55.8%
3Y
+30.6%
1Y
+110.0%
6M
+75.0%
1M
+0.8%
1W
+0.2%
ALK
Alkermes plc
Peer
5Y
+40.1%
3Y
+3.5%
1Y
-17.4%
6M
+2.9%
1M
-20.5%
1W
-3.0%
RDN
RadNet, Inc.
Peer
5Y
+171.5%
3Y
+117.6%
1Y
+21.3%
6M
-21.5%
1M
-2.6%
1W
+8.9%
MMS
Merit Medical Systems, Inc.
Peer
5Y
+15.0%
3Y
-8.9%
1Y
-24.4%
6M
-12.4%
1M
+2.0%
1W
+4.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
22.32
Forward P/E
13.33
PEG Ratio
1.51
P/B Ratio
3.35
P/S Ratio
0.79
EV/Revenue
0.97
EV/EBITDA
13.38
Market Cap
$4.45B
Profitability
Profit margins and return metrics
Profit Margin
3.67%
Operating Margin
6.24%
Gross Margin
19.26%
ROE
15.2%
ROA
6.14%
Growth
Revenue and earnings growth rates
Revenue Growth
+8.8%
Earnings Growth
+1.3%
Q/Q Revenue Growth
+8.84%
Q/Q Earnings Growth
-2.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.96
Moderate
Current Ratio
1.52
Good
Quick Ratio
0.9
Poor
Cash/Share
$1.52
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.5B
Gross Margin
19.3%
Op. Margin
6.2%
Net Margin
4.0%
Total Assets
$3.5B
Liabilities
$2.1B
Equity
$1.3B
Debt/Equity
1.61x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
62%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-24
$0.46
-1.8% surprise
2025-10-30
$0.32
-5.9% surprise
2025-07-30
$0.41
+3.3% surprise
Healthcare Sector Comparison
Comparing OPCH against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
P/E Ratio
22.32
This Stock
vs
89.02
Sector Avg
-74.9%
(Discount)
Return on Equity (ROE)
15.2%
This Stock
vs
-100.15%
Sector Avg
-115.2%
(Below Avg)
Profit Margin
3.67%
This Stock
vs
-13.63%
Sector Avg
-127.0%
(Weaker)
Debt to Equity
0.96
This Stock
vs
3.22
Sector Avg
-70.2%
(Less Debt)
Revenue Growth
8.8%
This Stock
vs
121.05%
Sector Avg
-92.7%
(Slower)
Current Ratio
1.52
This Stock
vs
4.55
Sector Avg
-66.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OPCH
Option Care Health, Inc.
|
NEUTRAL | $4.45B | 22.32 | 15.2% | 3.7% | $28.34 | |
|
FOLD
Amicus Therapeutics, Inc.
|
BEARISH | $4.54B | - | -11.6% | -4.3% | $14.47 | Compare |
|
ALKS
Alkermes plc
|
BEARISH | $4.63B | 19.41 | 14.7% | 16.4% | $27.76 | Compare |
|
RDNT
RadNet, Inc.
|
BEARISH | $4.69B | - | 1.4% | -0.9% | $60.39 | Compare |
|
MMSI
Merit Medical Systems, Inc.
|
NEUTRAL | $4.21B | 33.12 | 8.7% | 8.5% | $70.54 | Compare |
OPCH
Option Care Health, Inc.
NEUTRAL
Mkt Cap
$4.4B
P/E
22.3
ROE
15.2%
Price
$28.34
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | PATE R CARTER | Director | Sale | 30,287 | $970,620 |
| 2026-02-27 | BAVARO MICHAEL | Officer | Sale | 6,000 | $198,000 |
| 2026-02-20 | RADEMACHER JOHN CHARLES | Chief Executive Officer | Stock Award | 11,087 | - |
| 2026-02-18 | SETHNA MEENAL | Chief Financial Officer | Stock Award | 27,045 | - |
| 2026-02-18 | RADEMACHER JOHN CHARLES | Chief Executive Officer | Stock Award | 78,876 | - |
| 2026-02-18 | SMYSER COLLIN | General Counsel | Stock Award | 15,213 | - |
| 2026-02-18 | WHITWORTH LUKE | Chief Operating Officer | Stock Award | 30,423 | - |
| 2026-02-18 | BAVARO MICHAEL | Officer | Stock Award | 9,579 | - |
| 2026-02-18 | GRASHOFF CHRISTOPHER L | Officer | Stock Award | 12,678 | - |
| 2026-02-18 | ADEWUNMI FEMI | Officer | Stock Award | 9,579 | - |
| 2026-02-18 | MAGGIO NICOLE | Officer | Stock Award | 4,226 | - |
| 2025-11-03 | KRAEMER HARRY M. JANSEN JR. | Director | Purchase | 38,000 | $987,392 |
PATE R CARTER
Director
2026-02-27
30,287 shares
·
$970,620
BAVARO MICHAEL
Officer
2026-02-27
6,000 shares
·
$198,000
RADEMACHER JOHN CHARLES
Chief Executive Officer
2026-02-20
11,087 shares
SETHNA MEENAL
Chief Financial Officer
2026-02-18
27,045 shares
RADEMACHER JOHN CHARLES
Chief Executive Officer
2026-02-18
78,876 shares
SMYSER COLLIN
General Counsel
2026-02-18
15,213 shares
WHITWORTH LUKE
Chief Operating Officer
2026-02-18
30,423 shares
BAVARO MICHAEL
Officer
2026-02-18
9,579 shares
GRASHOFF CHRISTOPHER L
Officer
2026-02-18
12,678 shares
ADEWUNMI FEMI
Officer
2026-02-18
9,579 shares
MAGGIO NICOLE
Officer
2026-02-18
4,226 shares
KRAEMER HARRY M. JANSEN JR.
Director
2025-11-03
38,000 shares
·
$987,392
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
11 analysts
Barrington Research
2026-01-16
Outperform
Outperform
Morgan Stanley
2026-01-13
Overweight
Overweight
Citizens
2026-01-13
Market Outperform
Market Outperform
Stephens & Co.
2025-12-11
Overweight
B of A Securities
2025-12-09
Buy
Buy
Deutsche Bank
2025-12-09
Buy
Buy
TD Cowen
2025-11-03
Hold
Hold
Citizens
2025-10-31
Market Outperform
Market Outperform
Barrington Research
2025-10-31
Outperform
Outperform
Past News Coverage
Recent headlines mentioning OPCH from our newsroom.
Newest → oldest
No matching news yet.